Login / Signup

Immunogenicity of MultiTEP platform technology-based Tau vaccine in non-human primates.

Armine HovakimyanKaren ZagorskiGor ChailyanTatevik AntonyanLevon MelikyanIrina PetrushinaDash G BattOlga KingManush GhazaryanAashrit DonthiCaitlynn FooseNikolai PetrovskyDavid H CribbsMichael G AgadjanyanAnahit Ghochikyan
Published in: NPJ vaccines (2022)
Pathological forms of Tau protein are directly associated with neurodegeneration and correlate with Alzheimer's Disease (AD) symptoms, progression, and severity. Previously, using various mouse models of Tauopathies and AD, we have demonstrated the immunogenicity and efficacy of the MultiTEP-based adjuvanted vaccine targeting the phosphatase activating domain (PAD) of Tau, AV-1980R/A. Here, we analyzed its immunogenicity in non-human primates (NHP), the closest phylogenic relatives to humans with a similar immune system, to initiate the transition of this vaccine into clinical trials. We have demonstrated that AV-1980R/A is highly immunogenic in these NHPs, activating a broad but unique to each monkey repertoire of MultiTEP-specific T helper (Th) cells that, in turn, activate B cells specific to PAD. The resulting anti-PAD IgG antibodies recognize pathological Tau tangles and Tau-positive neuritis in AD case brain sections with no staining in control non-AD cases. These published data and efficacy results support the AV-1980R/A vaccine progression to first-in-human clinical trials.
Keyphrases